Hoth Therapeutics, Inc. (NASDAQ: HOTH) Dermatological therapeutics pipeline targeting multi-billion dollar opportunities (+ near-term catalysts)

Hoth Therapeutics, Inc. (NASDAQ: HOTH) will be a featured presenter at Wall Street Reporter’s Next Super Stock Live! online investor conference on September 26, 2019. 

 

 

Robb Knie, CEO

 

 

 

 

Hoth Therapeutics, Inc. (NASDAQ: HOTH) Interview with CEO Robb Knie, discussing the company’s pipeline of unique targeted dermatological therapies, for indications including: eczema, psoriasis, chronic wound disorders, and acne which address multi-billion dollar market opportunities.

Robb provides an overview of the company’s BioLexa platform, and how it offers a shortened path towards regulatory approval, and the near-term catalysts for value creation.  

Robb, also explains why Hoth is a compelling value proposition for investors based on recent M&A activity  in the dermatological space, including the $4.9 billion paid by Pfizer (NYSE: PFE) for Anacor, whose lead product lead product, Eucrisa, is a topical treatment for mild to moderate eczema. 

Investor Presentation

septHoth-Therapeutics-Investor-Presentation-Spring-2019

 

Hoth Therapeutics, Inc. (NASDAQ: HOTH) will be a featured presenter at Wall Street Reporter’s Next Super Stock Live! online investor conference on September 26, 2019. Details to be announced shortly!